key: cord-0921723-af8ygodu authors: Mahmoud, Sally A.; Ganesan, Subhashini; Ibrahim, Esra; Thakre, Bhagyashree; Teddy, Juliet G.; Raheja, Preety; Zaher, Walid A. title: Evaluation of six different rapid methods for nucleic acid detection of SARS‐COV‐2 virus date: 2021-06-08 journal: J Med Virol DOI: 10.1002/jmv.27090 sha: 80b607be55fd66154b4b376973743a73db5cbeda doc_id: 921723 cord_uid: af8ygodu In the current coronavirus disease 2019 (COVID‐19) pandemic there is a mass screening of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) happening around the world due to the extensive spread of the infections. There is a high demand for rapid diagnostic tests to expedite the identification of cases and to facilitate early isolation and control spread. Hence this study evaluates six different rapid nucleic acid detection assays that are commercially available for SARS‐CoV‐2 virus detection. Nasopharyngeal samples were collected from 4981 participants and were tested for the SARS‐CoV‐2 virus by the gold standard real‐time reverse‐transcription polymerase chain reaction (RT‐PCR) method and with one of these six rapid methods of detection. Evaluation of the rapid nucleic acid detection assays was done by comparing the results of these rapid methods with the gold standard RT‐qPCR results for SARS‐COV‐2 detection. AQ‐TOP had the highest sensitivity (98%) and a strong kappa value of 0.943 followed by Genechecker and Abbot ID NOW. The POCKIT (ii RT‐PCR) assay had the highest test accuracy of 99.29% followed by Genechecker and Cobas Liat. Atila iAMP showed the highest percentage of invalid reports (35.5%) followed by AQ‐TOP with 6% and POCKIT with 3.7% of invalid reports. Genechecker system, Abbott ID NOW, and Cobas Liat were found to have the best performance and agreement when compared with the standard RT‐PCR for COVID‐19 detection. With further research, these rapid tests have the potential to be employed in large‐scale screening of COVID‐19. manpower, and long hours. In the current scenario of the pandemic, with such large numbers being affected conducting these tests with limited lab capacities is challenging. 2 The lab facilities are overburdened, and molecular testing is time-consuming, which delays reporting and that in turn impacts the containment of the spread. 3 Hence there is a demand for alternative testing strategies that are rapid and less sophisticated. 4 In SARS-CoV-2, human-to-human transmission is through droplets or direct contact 5 and its symptoms are very similar to flu, hence molecular tests are critical to differentiate and detect COVID-19 infections. In the early stages of infection, the viral load is usually high in patients and studies show that a single swab can contain more than a million viral particles, 6 hence nucleic acid testing is the most efficient form of testing in the early stages, and identifying infections earlier is vital. As mass testing, early detection, and isolation are crucial for containing the spread of infection, evaluation of these rapid tests becomes imperative. Currently, there are many nucleic acid detection assays that have obtained emergency authorization by the US Food and Drug Administration to detect SARS-CoV-2 and have been largely implemented around the globe. The study compares six different molecular tests that detect nuclear RNA of SARS-COV-2 and evaluate them against the standard RT-PCR. Board of the Department of Health, Abu Dhabi. The positive samples were collected from patients at the COVID-19 quarantine facilities who were tested positive for COVID-19 and were either asymptomatic or had mild symptoms. The negative samples were collected from people who visited the lab for screening for COVID-19 infections for travel and other purposes. The participants were approached randomly and whoever was willing to give consent was included in the study. After getting informed consent from the participants, their nasopharyngeal swabs (NPS) were collected. The standard RT-PCR requires a wet swab, for which a sterile nasopharyngeal swab was used for collection and then was placed into the universal transport medium. A dry swab is required for Abbott ID NOW and Atila iAMP COVID-19 detection tests. The Atila iAMP COVID-19 Detection Kit was provided with a dry swab that was used for collection and these swabs were transported to the lab in RNAase/DNAase free Eppendorf tubes. The FLOQSwabs (COPAN Flocked Swabs) dry swab was used for sample collection for Abbott ID NOW. This was done as a bedside test immediately after collection. All samples that were collected outside the lab were transported to the lab immediately. Table 1 . The results of the standard RT-qPCR were used as a standard reference and the results obtained from the rapid methods were compared to the standard reference reports. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were calculated for each method. The sensitivity, specificity, PPV, NPV, and accuracy were calculated for the six rapid methods by comparing with the standard RT-PCR results. The results are shown in Figure 1 . AQ-TOP and Genechecker had the highest sensitivity and PPV followed by the sensitivity of Abbott ID NOW and Cobas Liat. The Atila iAMP COVID-19 test had the lowest sensitivity. The POCKIT had the highest accuracy followed by Genechecker and Cobas Liat. The positive, negative, and overall agreement percentage along with Cohens' kappa value were calculated for the six methods and are presented in Table 2 . The positive percentage agreement with the standard RT-qPCR was strongest with AQ-TOP followed by Genechecker. Similarly, the negative agreement was best with POCKIT, Cobas Liat, and Genechecker. AQ-TOP. The overall agreement was highest with POCKIT and the Atila iAMP had the poorest agreement with the standard RT-PCR results. The number of positive cases missed, and details of the results reported invalid by the rapid tests are shown in Table 3 . Atila iAMP showed the highest percentage of invalid reports missing a large proportion (44.7%) of positive cases followed by AQ-TOP with 7% invalid reports. The Cobas Liat test did not show any invalid reports. In this ongoing COVID-19 pandemic with the extensive transmission of infection, rapid molecular tests are very crucial for early identification and isolation. The molecular assays evaluated in this study are all rapid with low complexity and thus require less hands-on time, which is the need of the hour, hence assays were evaluated in comparison with the standard RT-PCR. Our study found that the sensitivity of the Atila iAMP assay was very low. The Atila iAMP assay has been claimed to have around 87% PPA and 100% NPA with the reference RT-PCR assay, 7 but in this study, we found that the sensitivity was very low, and it reported a high number of invalid results, missing more than 40% of positive cases when compared with the standard RT-qPCR results. The reasons for a high rate of invalid reports were unclear; however, the lack of extraction and amplification inhibitors, which can lead to inadequate amplification could be reasons that need further exploration. 8, 9 The agreement percentage (kappa agreement) with the NPS results was low. In this assay, 93 positive samples were reported as either negative or invalid and the mean Ct value of these positive The study has evaluated commercial assays available in the market for rapid detection of SARS-COV-2, which is the need of the hour. All the results are compared with the gold standard RT-PCR recommended for SARS-COV-2 detection, which gives an insight into the performance of these rapid methods based on the standard comparison. Cobas Liat, Abbott ID NOW, and Genechecker system had the least number of invalid reports; however, the throughput for each is 1, 1, and 4 samples, respectively. Further studies analyzing all these parameters are needed, to consider implementing these rapid tests on a large scale for the detection of SARS-CoV-2. The study was not funded by any funding body, it was done in the Biogenix lab as a part of the research. The authors declare that there are no conflict of interests. The Ethics approval was obtained from the Department of Health (DOH) Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Laboratory testing strategy recommendations for COVID-19. Interim guidance 2019 novel coronavirus disease (COVID-19): paving the road for rapid detection and point-of-care diagnostics The proximal origin of SARS-CoV-2 Virological assessment of hospitalized patients with COVID-2019 Comparison of a laboratory-developed test targeting the envelope gene with three nucleic acid amplification tests for detection of SARS-CoV-2 Rapid direct nucleic acid amplification test without RNA extraction for SARS-CoV-2 using a portable PCR thermocycler Comparative study of sensitivity, linearity, and resistance to inhibition of digital and nondigital polymerase chain reaction and loop mediated isothermal amplification assays for quantification of human cytomegalovirus Clinical evaluation of three sample-to-answer platforms for detection of SARS-CoV-2 Evaluation of rapid diagnosis of novel coronavirus disease (COVID-19) using loopmediated isothermal amplification Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection Comparison of Abbott ID Now, DiaSorin Simplexa, and CDC FDA emergency use authorization methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19 Performance of Abbott ID Now COVID-19 rapid nucleic acid amplification test using nasopharyngeal swabs transported in viral transport media and dry nasal swabs in a New York City academic institution Development optimization and validation of RT-LAMP based COVID-19 facility in Pakistan Clinical performance of the point-of-care COBAS liat for detection of SARS-CoV-2 in 20 minutes: a multicenter study medical-devices/letters-health-care-providers/potential-false-resultsroche-molecular-systems-inc-cobas-sars-cov-2-influenza-test-use-cobasliat?utm_medium===email&utm_source=govdelivery Clinical validation of an automated reverse transcription-insulated isothermal PCR assay for the detection of severe acute respiratory syndrome coronavirus 2 [published online ahead of print Evaluation of six different rapid methods for nucleic acid detection of SARS-COV-2 virus